Persistent morbidity in Clade IIb mpox patients: interim results of a long-term follow-up study, Belgium, June to November 2022
- PMID: 36795501
- PMCID: PMC9936596
- DOI: 10.2807/1560-7917.ES.2023.28.7.2300072
Persistent morbidity in Clade IIb mpox patients: interim results of a long-term follow-up study, Belgium, June to November 2022
Abstract
While mpox was well characterised during the 2022 global Clade IIb outbreak, little is known about persistent morbidity. We present interim results of a prospective cohort study of 95 mpox patients assessed 3-20 weeks post-symptom onset. Two-thirds of participants had residual morbidity, including 25 with persistent anorectal and 18 with genital symptoms. Loss of physical fitness, new-onset/worsened fatigue and mental health problems were reported in 36, 19 and 11 patients, respectively. These findings require attention by healthcare providers.
Keywords: fatigue; follow-up; long-term follow-up; medium-term follow-up; monkeypox; mpox; sequelae.
Conflict of interest statement
Figures
References
-
- European Centre for Disease Prevention and Control (ECDC). Joint ECDC-WHO Regional Office for Europe Mpox Surveillance Bulletin: 18 January 2023. Stockholm: ECDC. [Accessed: 30 Jan 2023]. Available from: https://monkeypoxreport.ecdc.europa.eu
MeSH terms
LinkOut - more resources
Full Text Sources
Medical